Sign in with Google. Opens in new tab
ENTITY
Astellas Pharma

Astellas Pharma (4503 JP)

157
Analysis
Health CareJapan
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia
more
bullishAstellas Pharma
15 Jul 2025 00:30

Astellas Pharma (4503 JP): Izervay on Strong Footing, Strategic Brands Key for Future

​Astellas sees 25% growth in Q1FY26 sales of Izervay in the U.S. In FY25, revenue from strategic brands improved 110% YoY. Izervay Q1FY26 revenue...

Logo
320 Views
Share
bullishAstellas Pharma
28 Apr 2025 08:12

Astellas Pharma (4503 JP): Strong FY25 Result; Cost Optimization to Boost FY26 Profit on Flat Sales

​Astellas Pharma reports FY25 performance, with key parameters surpassing guidance. The company expects 1% revenue growth in FY26, while core...

Logo
281 Views
Share
21 Jul 2025 00:30

Ono Pharmaceutical (4528 JP): Label Expansion Helps, But Long-Term Growth Momentum Calls for More

​Ono Pharmaceutical expects 4% YoY growth in Opdivo revenue for FY26, driven by indication expansion but faces long-term concerns due to smaller...

Logo
249 Views
Share
bullishAstellas Pharma
08 Feb 2025 00:30

Astellas Pharma (4503 JP): 9MFY25 Result- Strategic Brands Strong; Margins Expand; Guidance Raised

​Astellas Pharma reports strong revenue growth and profit increase in 9MFY25, with U.S. market being the key contributor. Guidance revised upward...

Logo
588 Views
Share
bullishAstellas Pharma
25 Jan 2025 00:30

Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt

​Astellas Pharma raises FY25 revenue guidance to ¥1900B from ¥1,800B. The company is recording ¥176B impairment charge for intangible assets, which...

Logo
557 Views
Share
x